{
  "trial_id": "breast_cancer_her2_positive",
  "generated_mappings": [
    {
      "resourceType": "Observation",
      "mcode_element": "PrimaryCancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "primarycancercondition",
        "display": "PrimaryCancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "The text explicitly states 'HER2-Positive Breast Cancer', which is a primary cancer condition with HER2 biomarker status specified.",
      "id": "199dce28-cef0-49a9-bfe6-f6c9371162c4"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "SecondaryCancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "secondarycancercondition",
        "display": "SecondaryCancerCondition"
      },
      "value": "Metastatic Breast Cancer",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "The term 'Metastatic Breast Cancer' indicates the cancer has spread beyond the primary site, qualifying as a secondary cancer condition in mCODE.",
      "id": "0b63900b-f6fc-4c8d-add3-c71049e84fb3"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "Metastatic",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "The presence of metastasis indicates an advanced disease status, which is captured in the CancerDiseaseStatus element.",
      "id": "b0e07b86-078f-4a0e-978c-b38ff3508669"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "HER2Status",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "her2status",
        "display": "HER2Status"
      },
      "value": "Positive",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "The text specifies 'HER2-Positive', which directly maps to the HER2Status element indicating positive biomarker status.",
      "id": "633e752d-2097-4d92-a359-07491b29a3d0"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "present",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "Text explicitly states metastatic breast cancer, indicating presence of metastatic disease",
      "id": "02495dfe-90ce-4c96-81d3-92c65c9d0852"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "HER2ReceptorStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "her2receptorstatus",
        "display": "HER2ReceptorStatus"
      },
      "value": "positive",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "Text explicitly states HER2-positive status for breast cancer",
      "id": "cbb3a78b-0bee-447b-a03f-19a3ddc7457a"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "ECOGPerformanceStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "ecogperformancestatus",
        "display": "ECOGPerformanceStatus"
      },
      "value": "0-1",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "Text specifies ECOG performance status range of 0-1 as inclusion criterion",
      "id": "157992c1-232c-4a75-9cf9-15e87d3024a3"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerRelatedComorbidities",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "cancerrelatedcomorbidities",
        "display": "CancerRelatedComorbidities"
      },
      "value": "absent",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "Active brain metastases are listed as exclusion criterion, implying absence is required",
      "id": "97e2a335-2edc-4d76-8ed0-9d275c535024"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerRelatedMedicationStatement",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "cancerrelatedmedicationstatement",
        "display": "CancerRelatedMedicationStatement"
      },
      "value": "not administered",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "Prior treatment with Trastuzumab Deruxtecan is listed as exclusion criterion",
      "id": "16f85f65-b4fc-4f59-99b0-01ebcf81593c"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "PregnancyStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "pregnancystatus",
        "display": "PregnancyStatus"
      },
      "value": "not pregnant",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "Pregnancy is listed as exclusion criterion, implying non-pregnant status is required",
      "id": "7a00f4f4-5583-466f-8378-60a5f756f128"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "PrimaryCancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "primarycancercondition",
        "display": "PrimaryCancerCondition"
      },
      "value": "Metastatic breast cancer",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "The text explicitly mentions 'metastatic breast cancer' as the patient condition being studied",
      "id": "a3fb3db0-0f73-4a72-8979-ecb913ce73e8"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "Progressive disease",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "The text indicates disease progression on prior therapy, which corresponds to progressive disease status",
      "id": "fab865b9-6ab5-4e7f-9f26-490aae0c4046"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "HER2Status",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "her2status",
        "display": "HER2Status"
      },
      "value": "Positive",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "The text explicitly states 'HER2-positive' as a characteristic of the breast cancer being studied",
      "id": "0ff5ba9c-7aca-498c-8b32-8e88d0fcf0ee"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerRelatedMedicationStatement",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "cancerrelatedmedicationstatement",
        "display": "CancerRelatedMedicationStatement"
      },
      "value": "Prior therapy",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "The text mentions trastuzumab as a prior therapy that patients have progressed on",
      "id": "ec923d4c-2469-4e17-a55c-79a0a176c97e"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerRelatedMedicationStatement",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "cancerrelatedmedicationstatement",
        "display": "CancerRelatedMedicationStatement"
      },
      "value": "Novel therapy under investigation",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "The text describes a novel HER2-targeted therapy being evaluated in the study",
      "id": "37ec2a11-a0fb-44ea-8109-447203f18403"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "PrimaryCancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "primarycancercondition",
        "display": "PrimaryCancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "The text explicitly states 'HER2-Positive Breast Cancer' which maps to a primary cancer condition with HER2 biomarker status",
      "id": "fe2d66e8-95f7-4d28-95d3-a0c4a0d5d587"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "Metastatic",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "The term 'Metastatic' indicates advanced disease status with distant spread",
      "id": "03cb458e-db72-4c0e-8c3d-d76af82635a8"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "Positive",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "HER2-Positive indicates a specific genomic variant status relevant for targeted therapy",
      "id": "3dfaafc1-2585-4917-bbbb-de97e7c1c867"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerRelatedSurgicalProcedure",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "cancerrelatedsurgicalprocedure",
        "display": "CancerRelatedSurgicalProcedure"
      },
      "value": "Phase III Study",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "Clinical trial participation is a cancer-related procedure/intervention, though the specific therapy details are not provided",
      "id": "1dc131d0-712c-4e7a-93be-1e54c34cac71"
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerRelatedMedicationStatement",
      "code": {
        "system": "http://hl7.org/fhir/us/mCODE",
        "code": "cancerrelatedmedicationstatement",
        "display": "CancerRelatedMedicationStatement"
      },
      "value": "Novel Targeted Therapy",
      "mapping_confidence": 0.0,
      "source_text_fragment": "Entity index unknown",
      "mapping_rationale": "Targeted therapy is mentioned as the intervention, though specific medication details are not provided in the text",
      "id": "fb5bb97d-e6eb-41ba-8990-26be53656ff7"
    }
  ],
  "expected_mappings": [
    {
      "source_entity_index": 0,
      "mcode_element": "CancerCondition",
      "value": "HER2-Positive Breast Cancer",
      "confidence": 0.95,
      "mapping_rationale": "Primary cancer diagnosis with HER2 biomarker status"
    },
    {
      "source_entity_index": 1,
      "mcode_element": "CancerCondition",
      "value": "Metastatic Breast Cancer",
      "confidence": 0.95,
      "mapping_rationale": "Metastatic cancer condition"
    },
    {
      "source_entity_index": 2,
      "mcode_element": "CancerCondition",
      "value": "HER2-positive metastatic breast cancer",
      "confidence": 0.9,
      "mapping_rationale": "Specific cancer diagnosis with biomarker and metastatic status"
    },
    {
      "source_entity_index": 3,
      "mcode_element": "CancerDiseaseStatus",
      "value": "Measurable disease present",
      "confidence": 0.85,
      "mapping_rationale": "Disease status indicating measurable disease"
    },
    {
      "source_entity_index": 4,
      "mcode_element": "ECOGPerformanceStatus",
      "value": "0-1",
      "confidence": 0.9,
      "mapping_rationale": "ECOG performance status score range"
    },
    {
      "source_entity_index": 5,
      "mcode_element": "Observation",
      "value": "Adequate organ function",
      "confidence": 0.8,
      "mapping_rationale": "General observation about organ function status"
    },
    {
      "source_entity_index": 10,
      "mcode_element": "CancerRelatedMedication",
      "value": "Trastuzumab Deruxtecan",
      "confidence": 0.95,
      "mapping_rationale": "HER2-targeted antibody-drug conjugate medication"
    },
    {
      "source_entity_index": 11,
      "mcode_element": "CancerRelatedMedication",
      "value": "Trastuzumab",
      "confidence": 0.9,
      "mapping_rationale": "Standard HER2-targeted therapy medication"
    },
    {
      "source_entity_index": 12,
      "mcode_element": "CancerRelatedMedication",
      "value": "Taxane chemotherapy",
      "confidence": 0.85,
      "mapping_rationale": "Chemotherapy backbone medication"
    },
    {
      "source_entity_index": 13,
      "mcode_element": "CancerRelatedMedication",
      "value": "HER2-targeted therapy",
      "confidence": 0.9,
      "mapping_rationale": "General category of HER2-targeted treatments"
    },
    {
      "source_entity_index": 14,
      "mcode_element": "CancerCondition",
      "value": "HER2-positive metastatic breast cancer",
      "confidence": 0.95,
      "mapping_rationale": "Cancer condition from description section"
    },
    {
      "source_entity_index": 15,
      "mcode_element": "CancerRelatedMedication",
      "value": "Trastuzumab-based therapy",
      "confidence": 0.9,
      "mapping_rationale": "Prior treatment regimen based on trastuzumab"
    }
  ]
}